AIRLINK 72.25 Increased By ▲ 3.05 (4.41%)
BOP 5.06 Increased By ▲ 0.16 (3.27%)
CNERGY 4.33 Increased By ▲ 0.07 (1.64%)
DFML 31.50 Increased By ▲ 0.25 (0.8%)
DGKC 80.80 Increased By ▲ 3.55 (4.6%)
FCCL 21.01 Increased By ▲ 1.01 (5.05%)
FFBL 34.94 Decreased By ▼ -0.06 (-0.17%)
FFL 9.25 Increased By ▲ 0.13 (1.43%)
GGL 9.99 Increased By ▲ 0.19 (1.94%)
HBL 113.50 Increased By ▲ 0.74 (0.66%)
HUBC 134.95 Increased By ▲ 1.91 (1.44%)
HUMNL 7.05 Increased By ▲ 0.10 (1.44%)
KEL 4.38 Increased By ▲ 0.15 (3.55%)
KOSM 4.42 Increased By ▲ 0.17 (4%)
MLCF 37.42 Increased By ▲ 0.82 (2.24%)
OGDC 136.21 Increased By ▲ 3.34 (2.51%)
PAEL 23.79 Increased By ▲ 1.15 (5.08%)
PIAA 24.72 Increased By ▲ 0.52 (2.15%)
PIBTL 6.52 Increased By ▲ 0.06 (0.93%)
PPL 120.90 Increased By ▲ 4.60 (3.96%)
PRL 26.38 Increased By ▲ 0.48 (1.85%)
PTC 13.35 Increased By ▲ 0.27 (2.06%)
SEARL 52.60 Increased By ▲ 0.60 (1.15%)
SNGP 71.30 Increased By ▲ 3.70 (5.47%)
SSGC 10.65 Increased By ▲ 0.11 (1.04%)
TELE 8.43 Increased By ▲ 0.15 (1.81%)
TPLP 11.07 Increased By ▲ 0.27 (2.5%)
TRG 61.50 Increased By ▲ 2.21 (3.73%)
UNITY 25.12 Decreased By ▼ -0.01 (-0.04%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,509 Increased By 100.7 (1.36%)
BR30 24,581 Increased By 544.6 (2.27%)
KSE100 71,723 Increased By 1055.9 (1.49%)
KSE30 23,510 Increased By 286.3 (1.23%)

SYDNEY: Australia has secured access to a "promising" potential coronavirus vaccine, the prime minister announced Tuesday, saying the country would manufacture it and offer free doses to the entire population.

Prime Minister Scott Morrison said Australia had reached a deal with Swedish-British pharmaceutical company AstraZeneca to receive the Covid-19 vaccine it is developing with Oxford University.

"The Oxford vaccine is one of the most advanced and promising in the world, and under this deal we have secured early access for every Australian," he said.

"If this vaccine proves successful we will manufacture and supply vaccines straight away under our own steam and make it free for 25 million Australians."

The Oxford vaccine is one of five globally in Phase 3 efficacy trials, and researchers hope to have results by the end of the year.

Comments

Comments are closed.